Antiphospholipid syndrome and cancer.
Thrombosis is a frequent complication of cancer that is a substantial cause of morbidity and mortality. The association of antiphospholipid antibodies (aPL) and cancer has been under investigation for several years. Recent findings suggest an increased prevalence of certain cancers in aPL-positive patients; thus, an intensive search for an occult malignancy is prompted in these patients. In addition, several studies reported on elevated levels of aPL in various malignancies; it seems, however, that aPL levels do not reflect their pathogenicity; therefore, their pathological significance in these subset of patients is still elusive. Continuing research on the association between the antiphospholipid syndrome/aPL and malignancies is important, given the potential impact on the understanding and treatment of both antiphospholipid syndrome and cancer.
Reinstein
Eyal
E
Department of Internal Medicine B and Center for Autoimmune Diseases, Chaim Sheba Medical Center, Tel-Hashomer 52621, Israel. eyalre@post.tau.ac.il
Shoenfeld
Yehuda
Y
D017152:Antibodies, Antiphospholipid; D016736:Antiphospholipid Syndrome / Q000150:complications / Q000276:immunology; D006801:Humans; D009369:Neoplasms / Q000209:etiology / Q000276:immunology; D013927:Thrombosis / Q000150:complications
D017152:Antibodies, Antiphospholipid